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Summary.-Detailed serological studies have been undertaken in a small group of
cancer patients receiving nonspecific immunotherapy with Corynebacterium parvum
(C. parvum). These patients included 4 cases ofrecurrent malignant melanoma, 2 of
stomach cancer and 2 of recurrent breast cancer. They all received an initial i.v.
infusion of 20 mg of aformol killed suspension of C. parvum followed by2 mg (i.m.)
at weekly intervals for 10-11 weeks.
This protocol consistently resulted in an increase in the circulating IgG levels of
all patients but had a variable effect on their IgA, IgM and IgE levels. Increases in
the concentration of all 4 IgG subclasses contributed to the overall increase in IgG
levels and these changes ranked IgG2>IgGl>IgG3= IgG4. It also had an in-
consistent effect upon the levels of a-macroglobulin in pregnancy but the levels of
normal serum a2-macroglobulin were virtually unchanged.
Pre-existing antibodies to C. parvum were noted in all the patients. Titres rose
appreciably following C. parvum administration and remained at high, though
fluctuating levels, throughout the 100-day period of observation. Absorption
studies suggested that the development of antibodies to C. parvum accounted in part
for the increased IgG levels noted following this form of therapy. The significance
ofthese changes in relation tothepossible anti-tumoureffect of C.parvum isdiscussed.
DURING recent years, considerable
interest has been shown in the use of
adjuvants such as BCG for specific and
nonspecific immunotherapy of tumours in
man (for example, Morton et al., 1970;
Mathe et al., 1973; Gutterman et al., 1973).
Our own attention has been focussed upon
the possible clinical value of formol killed
suspensions of C. parvurm. Detailed
studies undertaken in mice have demon-
strated convincingly that these pre-
parations can inhibit the growth of
transplanted syngeneic tumours of both
chemical and viral origin (Woodruff and
Boak, 1966; Halpern et al., 1966; Wood-
ruff and Dunbar, 1973). On the basis of
the experience gained in animal tumour
systems, we have recently administered
C. parvum to a limited number of cancer
patients with poor prognosis. Although
it is still too early to assess the clinical
value of the treatment used, we report in
the present paper the results of detailed
serological studies we have undertaken in
some of these patients, not only because
they are of some fundamental importance
but also as a guide to other investigators
in this field.
During these studies we have deter-
mined the effect of repeated C. parvurm
administration on the levels of immuno-
globulin classes and other serum proteins.EFFECT OF C. PARVUM THERAPY ON IMMUNOGLOBULIN LEVELS
Furthermore, because the IgG subclasses
(namely IgGI, IgG2, IgG3 and IgG4)
differ widely in their in vitro and in vivo
properties (Spiegelberg, 1974), including
their capacity to block the cell mediated
destruction of tumour cells in vitro (Jose
and Skvaril, 1974), we have also investi-
gated the effect ofC. parvum therapy upon
individual IgG subclass levels. As far as
we are aware, the present results are the
first reporting the effects of any form of
immunotherapy onsubclass levels. Finally,
we have also monitored the patients' sera
for antibodies to C. parvum and have
attempted to assess the relevance of these
to the immunoglobulin changes.
MATERIALS AND METHODS
The 8 patients studied comprised 2 with
locally recurrent breast cancer following 3-4
years after simple mastectomy and radio-
therapy (G.W. and E.B.); 4 with malignant
melanoma who, 9 months to 9 years after the
initial tumour, had extensive lymph node
involvement, local recurrence or multiple
subcutaneous metastases, or some combin-
ation of these (M.S., M.F., R.B., A.J.); and 2
with carcinoma ofthe stomach with extensive
lymph node involvement who were treated by
gastrectomy 9 days (E.P.) and 21 days (J.J.)
previously. Clinical data concerning these
and other patients treated with C. parvum
will be reported fully in due course.
The serum protein levels observed before
therapy are recorded in Table I. With the
exception of G.W. (see later), all patients
received an initial i.v. infusion of 20 mg of a
formol killed suspension of C. parvum
followed by 2 mg (i.m.) at weekly intervals for
10-11 weeks. The C. parvum used (CN6134
Batch EZ174) was supplied by the Wellcome
Research Laboratories, Langley Court,
Beckenham. To minimize the febrile
reactions which often follow i.v. adminis-
tration of C. parvum (Woodruff et al., 1974a),
the patients also received aspirin. On one
occasion (patient M.S.) the administration of
C. parvum was temporarily suspended for 2
weeks because of the appearance of a skin
rash. One patient (G.W.) had received a
single i.v. infusion of 47*6 mg of C. parvum
some 5 months before commencing the
weekly course of intramuscular injections.
The serum samples for analysis were always
obtained immediately before each C. parvum
injection and were stored at -20°C before
assay.
The IgM, IgA, IgG, IgG subclass and
oc2M levels in the sera were determined by the
Mancini radial immunodiffusion technique
(Mancini, Carbonara and Heremans, 1965).
A complete range of standards was included
on every plate and all the test samples were
assayed in duplicate. The antisera to IgG,
IgA and IgM were purchased from Wellcome
Reagents Ltd, Langley Court, Beckenham,
while the antiserum to a2M was produced in
our own laboratory as previously described
(Tunstall et al., 1975). The IgG, IgA and
IgM reference standards were obtained from
Hoechst Pharmaceuticals, Hounslow, while
the ac2M standard was purchased from
Melloy Laboratories, Springfield, Virginia,
U.S.A. The preparation and properties of
the antisera to the IgG subclasses and the
standard antigens used in their assay are
fully described elsewhere (Shakib et al., 1975).
The IgE levels were determined by a
radioimmunoassay procedure employing the
Phadebas IgE test kit (purchased from
Pharmacia G.B. Ltd, London). This assay
was performed according to the manu-
facturer's instructions.
The pregnancy oc-macroglobulin levels
were determined by an immunoassay pro-
cedure employing antibody-enzyme con-
jugates. This procedure has been described
in detail elsewhere (Stimson and Sinclair,
1974).
Antibodies to C. parvum were measured in
the sera by a latex agglutination test (Wood-
ruff, McBride and Dunbar, 1974b). The
results are expressed as log2 reciprocal of the
end point dilution. In certain instances sera
were fractionated on Sephadex G-200
columns and the presence of antibody
activity in the 19S, 1OS, 7S and 4 5S peaks
was assessed by the same technique. On
other occasions, dilutions of sera (see Tables
II and III) were absorbed at 37'C for 30 min
and overnight at 4°C (x 3) with one-tenth ofa
volume of packed C. parvum organisms.
Anti-C. parvum titres, IgG and IgG subclass
levels were measured before and after
absorption to give some indication of the
amount of IgG which was anti-C. parvum
antibody.
Screening for antinuclear factors was
performed by the qualitative rapid slide test
311K. JAMES ET AL.
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TABLE II.-The Effect of Absorption ofPatients' Sera with C. Parvum Upon IgG Levels
IgG before* IgG after Percent Pre-trial*
Patienit Time of sample absorptiont absorption decrease IgG
P.K.4 Pre-bleed 922 764 17
P.K. Pre-bleed 1031 812 19
EFP. Pre-bleed 1375 1161 16 1027
S.C. Day 21 988 549 44 538
J.J. Day 27 1853 1490 20 1366
R.R. Day 28 1967 1509 23 1434
AI.F. Day 28 1595 1003 37 1076
* IgG expressed as mg/100 ml.
t Sera wvere absorbed 3 times at a 1: 10 dilution with a 1:10 voltume of packed organisms. Absorption
was carrie(l out at 37°C for 30 min aind overnight at 4°C.
I Patient P.K. was a control.
Note: All anti-C. parvurm titres after absorption were<1og22 AB3 titre by the agglutination test.
(Hyland, California) while the presence or
absence of rheumatoid factor was established
by the latex slide test (Hoechst Pharma-
ceuticals, Hounslow, England). Sera positive
in the latex slide test were further examined
by the Rose-Waaler procedure employing
sensitized sheep cells (Cruickshank, 1969).
RESULTS
The effect of C. parvurn therapy on the
levels ofserum immunoglobulins and other
proteins is illustrated in Fig. 1-10. In all
the figures the protein levels have been
expressed as a percentage of the value
observed immediately before therapy
(Table I). For ease of presentation, we
have plotted only the changes noted
during the initial 50 days following
commencement of therapy, but in general
a similar pattern was apparent over the
entire period of observation (70-128
days).
In all cases, the administration of
C. parvum was accompanied by an increase
in the serum IgG level (Fig. 1). This
increase was often apparent within 2
weeks of the initial C. parvum injection
and the levels generally remained elevated
throughout the period of treatment. On
occasions, the IgG levels increased to
almost twice the pretreatment value (see
E.B.). The effect of C. parvumn on the
levels of other immunoglobulins was less
consistent. While the IgA levels in the
melanoma patients were essentially un-
changed, marked increases were noted in
both stomach cancer patients and one of
+
DAY
FIG. 1.-Percentage change in serum IgG
levels inC.parvurntreatedpatients (multiple
injections). Note that in all patients there
was an appreciable increase in IgG levels.
the patients with breast cancer (Fig. 2).
On the other hand, elevated IgM levels
were observed in 2/4 of the melanoma
patients and the 2 stomach cancer
patients, but not in the 2 patients with
breast cancer. The observations that the
increases in IgM levels did not necessarily
313K. JAMES ElT AL.
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DAY DAY
FIG'. 2. Percentage change in serum IgA
levels inC. parvum treatedpatients(mult,iple
injections). Note that the levels remained
fairly constant in melanoma patients but
Nvere markedly elevated in both st,omach
cancer patients and one patient (E.B.) with
breast cancer.
occuir in the first 2 weeks of therapy and
that they were generally transient in
nature and could sometimes be followed by
a sharp decline (see J.J. and M.S., Fig. 3)
were particularly interesting.
The IgE levels showed an initial early
increase in 4/7 patients but in all cases
this was followed by a decline. Indeed,
in 4 cases the IgE levels had fallen well
below their pretreatment values within 7
weeks of commencing therapy (see M.F.,
E.P., E.B. and J.J., Fig. 4). It should be
noted that the IgE levels in patient M.S.
were less than 4 I.U. in 7/8 assays per-
formed on serum samples obtained within
7 weeks of commencing therapy.
The effect of C. parvum therapy upon
IgG subclass levels is shown in Fig. 5-8.
The IgGI subclass level increased (29-
78%) in all patients except R.R. (Fig. 5)
although in 3 patients (M.F., A.J. and
Fi(:'. 3. Percentage change in serum IgM
levels in C. parvu)n treated patients (multi-
ple injections). Note the transient and
marked changes in some patients, e.g. J..,
M.S. an(d E.P.
G.W.) this was transient. The effect on
the IgG2 subclass was more dramatic and
lasting (Fig. 6). The levels of this
protein were increased in all patients and
in 3 individuals more than doubled.
Changes in IgG3 and IgG4 levels were
less marked, increases greater than 25%
being observed in only 3 and 2 patients
respectively (Fig. 7, 8).
The C. parvum protocol had a variable
effect on the levels of the 2 oc-macro-
globulins studied. In general, the serum
x2M levels were largely unchanged (Fig. 9),
this in itself being a good indication that
the changes observed in the levels of other
serum proteins were probably not due to
haemoconcentration or haemodilution.
In contrast, however, variations in preg-
nancy xM levels were noted (Fig. 10). In
5/6 cases there was an initial decline in the
level of this protein, followed by a return
to pretreatment values in 3 patients, a
marked increase in 2 melanoma patients
+
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FIG. 4. Percentage change in serum IgE
levels in C. parvumit treated patients (multi-
ple injections). Note the initial increase in
certain patients (e.g. J.J.) followed by a
marked decline at later stages (e.g. J.J.).
(M.S., M.F.) and a decline in the third
patient (R.R.).
All the patients investigated had pre-
existing antibodies to C. parvum (see
Fig. 11). The levels observed were
comparable with those noted in a panel of
46 normal donors (23 male and 23 female)
aged 51-60 years (mean log2+41 s.d.-
5* 8±0* 9). The very high levels noted in
patient G.W. were undoubtedly attribut-
able to prior treatment with C. parvum.
Examination of Sephadex G-200 fractions
of pretreatment sera indicated that the
pre-existing antibodies could be 19S (see
M.S., Fig. 12), 78 (see J.J.) or both (see
R.R.). Appreciable increases in antibody
titre occurred within 2 weeks of com-
mencing therapy, to reach an initial peak
titre at 4 weeks (see Fig. 11). Despite
repeated i.m. injections, titres tended to
Fic. 5. Percentage change in IgGI levels in
C. parvum treated patients. Note that in
all but one patient (R.R.) the IgGI level
increased after the initiation of C. parvumni
therapy. In certain patients this increase
was transient (A.J., A.F. and G.W.).
fall slightly after the initial peak and in
most cases continued to rise and fall in a
cyclical manner with a long but uncertain
periodicity. The antibodies evoked were
again ofeither the 19S or 78 class (Fig. 12).
It should also be noted that the response
of certain patients were rather poor (e.g.,
A.J., J.J. and M.S.).
The absorption of sera with C. parvum
resulted in an appreciable decrease in the
overall IgG levels (Table III) and also
affected the levels of individual IgG
subclasses (Table III). As was to be
expected, this decrease was most apparent
in sera obtained following the commence-
ment of therapy. These results suggest
that the development of antibodies to
C. parvum contributes to an appreciable
extent to the increased IgG and IgG
+
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-I- 200 + 135
DAY
FiPu;. 6. Percentage change in IgG2 levels in
C. parvuos treated patients. Note that the
level of this protein increased in all patients
and in certain instances the level more
than doubled (see M.S., E.B. and E.P.).
subclass levels noted following treatment
with this agent.
Our preliminary results also indicate
that the protocol used did not result in
gross production of antinuclear and
rheumatoid factor. In all 8 patients,
sera obtained within 28 days of com-
mencing therapy proved negative in the
antinuclear factor slide test. However, a
19S rheumatoid factor-like substance was
detected by the latex slide test in the sera
of one patient (M.F.) on Days 7 and 14.
This, however, had disappeared by Day
28. Because of this observation, we also
examined the sera from 6 other patients
(not included in this study) who had
received C. parvum. Similar positive
findings were observed on Days 7 and 14 in
2 of these patients. These also reverted
DAY
FiG. 7.-Percentage change in IgG3 levels in
C. parvum treated patients. Note that
while increased levels of this protein were
noted at some time during the period of
observation they exceeded 250% the pre-
treatment value in only 3 patients (M.S.,
E.P. and J.J.).
to being negative by Day 28. The sera
from these positive patients were
examined by the Rose-Waaler Test. All
titres increased initially from 1:5 to 1 : 30
and subsequently declined. Finally, one
ofthe additional 6 patients was positive by
the latex test before and after treatment.
However, during this time his Rose-
Waaler titre remained unchanged at 1: 5.
DISCUSSION
The results presented demonstrate
that the administration of C. parvum to
patients with cancer resulted in appreci-
able increases in their circulating IgG level
and had a variable effect upon the level of
other immunoglobulins, an observation
previously noted by others in 4 melanoma
patients receiving BCG therapy (Chess
317
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DAY
;ie(,. 8. Percenitage chanige il IggG4 levels in
C. parvum, tr eate(l patients. Note that the
levels of this protein increased above 2() %
in only 2 patients (E.B. an(l J.J.). In
one patient (M.F.) only trace levels of IgG4
-were (letecte(l.
et al., 1973). In addition, it resulted, as
might be expected, in the developmnent of
high levels of antibodies to C(. parvum.
The marked increase in IgG levels, in
particular of the IgG2 subclass shown in
these studies, is of interest as it would
seem reasonable to postulate that the
therapeutic value ofthis form oftreatment
may be influenced by changes in subclass
production. The IgG2 subc-lass is rela-
tively ineffective at fixing complement by
the direct pathway and does not readily
bind to monocytes or macroFhages, and is
therefore probably not too effective at
promoting opsonization (see Spiegelberg,
1974). From this point of view, its
preferential elicitation by (=,. parvum
would appear to be of little advantage to
aniy tumour cointrol mechanisms involviing
cytolysis or opsonization of tumour cells.
-*-*-MELANOMA
--A-A--BREAST CANCER
-*-*-STOMACH CANCER
0 10 20 30 lO 50
DAY
9ia. '. Percentagechange in serum c2M levels
in C. parvuoit treatedl patients (multiple
injections). Note that these remain fairly
constant thr oughouit the perio(l of obser-
vation.
In this respect it is interesting to note that
in vitro studies in murine systems strongly
suggest that the anti-tumour effect of
(. parvurm is exerted through macrophages
(Olivotto and Bomford, 1974; Ghaffar
et al., 1974; G(haffar, Cullen and Woodruff,
1975). On the other hand, Jose and
Skvaril (1974) have recently shown that
the antibodies in patients' sera which
blocked the cell mediated cytolysis of
autochthonous neuroblastoma cells were
localized in the main in the IgG and
IgG3 subclasses and present in small
amounts in the IgG4 subclass but absent
from the IgG2 component. While Jose
and Skvaril comment that this may
simply reflect a failure of tumour to elicit
IgG2 antibody, it is still conceivable that
(C. parvurm immunotherapy might favour
a switch away from the production of
blocking tumour antibodies and this could
be of benefit to the host.
rlThe effects of (Y. parcun nioted in the
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+
DAY
Fia. 10. Percentage change in serum preg-
nancy aAM levels in Cf. parvumn treated pat-
ients (multiple injections). Note that in
some patients the levels increased dramati-
cally (e.g. M.S., M.F.) while in others they
showed a marke(d (lecline.
preseiit study are somewhat differenit
from those observed following the treat-
ment of normal or tumour bearing mice
wNith this reagent (James, Willmott,
Milne and McBride-in preparation). In
normal CBA mice a single i.p. injection of
1*4 mg C. parvum results in a significant
increase in the IgG2b subclass alone (this
subclass is the mouse homologue ofhuman
IgG3). Depressed levels of IgM, IgA,
IgG1, IgG2a and 2b were observed in all
mice bearing transplanted syngeneic
methyleholanthrene induced fibrosarco-
mata. However, the administration of
C. partum 3 days after tumour cell
transplantation resulted in the IgG2b
level being elevated to values much
higher than observed in normal control
mice wvhile all the other immunoglobulins
rose to normal levels. Thus, in the
mouse the major effect of the C. parvum
protocol used was on the opsonizing and
complement fixing IgG2b subclass
(Spiegelberg, 1974). Further studies on
the immune response of mice to SRBC
(Warr and James, 1975) confirmed that
('. partium had a marked stimulatory
effect on the production ofIgG2b secreting
plaque forming cells while suppressing the
TITRE
(10g2)
0 20 40 60 80 100
DAYS
Fi(o. II.--Anti-C. parvum responses in C. parxvn treate(d patients (multiple injections). Log2 Ab
titres were measured by the end point ofagglutination. Note that all patients had background Ab
titres (Day 0) before injection an(i that the levels incieased clramatically following treatmeilt and
seemedl to fluctuate. -e 0 - AMelanoma; - A - breast cancer; * * stomach
cancer.
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IgM
(19S)
TITRE
(l9g2)
TITRE
(l092
DAYS
IgS
.76-
DAYS
FIG. 12. Immunoglobulin class of the anti-C. parvum responses in C. parvumn treated patients.
Log2 anti-C. parvum titres of Sephadex G-200 fractions ofpatients' sera were measured. Day 0 =
pre-bleed sample. Note that the pre-existing antibodies could be 19S (e.g. M.S.), 7S (e.g. J.J.) or
both (e.g. R.R.) and that following injection the response could be in the 19S and 7S fraction or
both. -0 *-Melanoma; -*-*- stomach cancer.
more thymus dependent IgGI response
(mouse IgGI is the homologue of human
IgG2). It is appreciated, however, that
the somewhat diverse effects of C. parvum
noted in man and mouse may reflect
differences in treatment protocols as well
as species variations.
The estimation of total IgG and
individual IgG subclass levels in patients
sera before and after absorption with
C. parvum indicated that increases in total
IgG and individual IgG subclasses were
attributable in part to the development of
specific antibodies to C. parvum.
Although these absorption studies are
only preliminary, the observation in
2 of 3 sera examined that the major
effect of absorption was on the IgG2
subclass level is of interest to previous
observations in man that the antibodies
elicited following challenge with carbo-
hydrate antigens are predominantly
associated with this subclass (Yount et al.,
1968). Thus, the marked increase in
IgG2 noted in the present study might
also represent a preferential subclass
response to the antigenic polysaccharide
component of C. parvum (Dawes, Tuach
and McBride, 1974) but absorption studies
will be necessary to establish this possibil-
ity. Furthermore, because of possible
nonspecific absorption effects, we cannot
excludethepossibilityof"nonspecific" IgG
synthesis that could follow lymphoid (or
morespecificallyB)cellhyperplasiainduced
by C. pzrvum. Such a response has been
suggested to occur following the adminis-
tration of some antigens as well as other
immunopotentiating agents (Humphrey,
1963; Moticka, 1974). The absence of
marked changes in autoantibody levels
and the levels ofpre-existing antibodies to
heterologous red cells and a panel of
common Esch. coli 0 antigens (personal
observations) tends to argue against the
stimulation of pre-existing clones by
C. parvum as contributing to a general Ig
increase; however, furtherworkisrequired
to clarify this potentially important issue.
At the present time we have no
satisfactory explanation for the inconsis-
tent changes noted in the levels of IgA,
IgM and IgE. While in the present
studies the IgE levels showed a transient
increase in a number of patients (for
example, J.J.), it should be stressed that
in one patient (not included in the present
study) with bronchogenic carcinoma a
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single i.v. injection of 46 8 mg of C.
parvum resulted in a 90-fold increase in
IgE levels. Subsequent investigations
revealed that this patient had a history of
allergic asthma, indicating that the
monitoring of IgE is both advisable and
informative. The observation that C.
parvum caused an increase in the IgA
levels ofboth stomach cancer patients and
one breast cancer patient, but was
without effect in the 4 melanoma patients
studied, is of interest and requires further
investigation.
The significance of the marked differ-
ences in the initial levels and subsequent
variations of pregnancy aM, remain to be
established. However, detailed studies
in other patients with tumours (W. H.
Stimson, unpublished) suggest that
increases in pregnancy aM areindicative of
tumour growth and metastases, whereas a
fall in the levels is suggestive of tumour
regression.
The presence of high levels of pre-
exisiting antibodies to C. parvum and their
marked increase following challenge with
this organism has previously been ob-
served in mice (Woodruff et al., 1974b).
This observation, together with in vitro
studies indicating that C. parvum may
activate both the classic and alternate
pathways of complement (McBride et al.,
1975), may account for some of the side-
reactions associated with the adminis-
tration ofthis material and emphasizes the
importance of monitoring the level of
these antibodies.
Another interesting point to arise from
this study was that from the limited
results we have to date, albeit using
relatively insensitive tests, the risk
of autoreactivity may not be as great as
might have been expected from animal
experiments (McCracken, McBride and
Weir, 1971; Cox and Keast, 1974;
McBride, Jones and Weir, 1974). Never-
theless, the observation that rheumatoid
factor-like substances may appear trans-
iently in C. parvum treated patients
highlights the importance of monitoring
the serum ofadjuvant treated patients for
autoantibodies. In this respect, the use
of more sensitive procedures than used in
the present study would be desirable, e.g.
the fluorescence procedure for antinuclear
factor.
This work was supported by grants
from the Cancer Research Campaign
(K.J., M.F.A.W. and W. McB.), the
Medical Research Council (L.D. and D.C.)
and the Scottish Home and Health
Department (W.H.S.). We acknowledge
the technical assistance of S. Tuach, J.
Merriman and I. Milne and are grateful to
our colleagues in the Royal Infirmary of
Edinburgh who referred patients for
treatment.
REFERENCES
CHESS, L., BOCK, G. N., UNGARO, P. C., BUCHHOLZ,
D. H. & MORDINEY, M. F. (1973) Immunological
Effects of BCG in Patients with Malignant
Melanoma: Specific Evidence for Stimulation of
" Secondary " Immune Responses. J. natn.
Cancer In8t., 51, 57.
Cox, K. 0. & KEAST, D. (1974) Studies of the
Corynebacterium parvum-associated Anaemia in
Mice. Clin. & exp. Immunol., 17, 199.
CRUICKSHANK, R. (1969) Medical Mic*obiology.
Edinburgh and London: E. & S. Livingstbne Ltd.
p. 917.
DAWES, J., TUACH, S. J. & MCBRIDE, W. H. (1974)
Properties of an Antigenic Polysaccharide from
Corynebacteriumparvum. J. Bact., 120, 24.
GHAFFAR, A., CULLEN, R. T., DUNBAR, N. &
WOODRUFF, M. F. A. (1974) Anti-tumour Effect
in vitro of Lymphocytes and Macrophages from
Alice Treated with Corynebacterium parvum.
Br. J. Cancer, 29, 199.
GHAFFAR, A., CULLEN, R. T. & WOODRUFF, M. F. A.
(1975) Further Studies on the Anti-tumour Effect
of Macrophages from Corynebacterium parvum-
treated mice. Br. J. Cancer, 31, 15.
GUTTERMAN, J. U., MAVLIGIT, G., McBRIDE, C.,
FRES, E., FREIREICH, E. J. & HERSH, E. M.
(1973) Active Immunotherapy with BCG for
Recurrent Melanoma. Lancet, i, 1208.
HALPERN, B. N., Biozzi, G., STIFFEL, C. & MOUTON,
D. (1966) Inhibition of Tumour Growth by
Administration of Killed Corynebacterium parvum.
Nature, Lond., 212, 853.
HUMPHREY, J. H. (1963) The Non-specific Globulin
Response to Freund's Adjuvant. In Tolerance
acquise et tolerance naturelle a l'egard de sub8tance8
antigeniques deftnies. Colloques, CNRS. p. 401.
JOSE, D. G. & SKVARIL, F. (1974) Serum Inhibitors
of Cellular Immunity in Human Neuroblastoma.
IgG Subclass of Blocking Acitivity. Int. J.
Cancer, 13, 173.322 K. JAMES ET'A.L.
MANCINI, G., CARBONARA, A. 0. & HEREMANS, J. F.
(1965) Immuno-chemical Quantitation ofAntigens
by Single Radial Immunodiffusion. Immuno-
chemistry, 2, 235.
MATHI, C., WEINER, R., POULLART, R., SCHWARZEN-
BERG, L., JASMIN, C., SCHNEIDER, M., HAYAT, M.,
AMIEL, J. L., DE VASSAL, F. & ROSENFELD, C.
(1973) BCG in Cancer Immunotherapy: Experi-
mental and Clinical Trials of its Use in Treatment
of Leukemia Minimal and or Residual Disease.
Natn. Cancer In8t. Monog., 39, 165.
MCBRIDE, W. H., JONES, J. T. & WEIR, D. M.
(1974) Increased Phagocytic Cell Activity and
Anaemia in Corynsbacterium parvum Treated
Mice. Br. J. exp. Path., 55, 38.
MCBRIDE, W. H., WEIR, D. M., KAY, A. B., PEARCE,
D. & CALDWELL, J. R. (1975) Activation of the
Classical and Alternate Pathways of Complement
by Corynebacteriuin parvum. Clin. & exp.
Immunol., 19, 143.
MCCRACKEN, A., McBRIDE, W. H. & WEIR, D. M.
(1971) Adjuvant Induced Anti-red Blood Cell
Activity in CBA Mice. Clin. & exp. Imnmunol.,
8, 949.
MORTON, D. L., EILBER, F. R., MALMGREN, R. A. &
WOOD, W. C. (1970) Immunological Factors
which Influence Response to Immunotherapy in
Malignant Melanoma. Surgery, St Louis, 68, 158.
MOTICKA, E. J. (1974) The Non-specific Stimulation
of Immunoglobulin Secretion following Specific
Stimulation of the Immune System. Immun-
ology, 27, 401.
OLIVOTTO, M. & BOMFORD, R. (1974) In vitro
Inhibition of Tumour Cell Growth and DNA
Synthesis by Peritoneal and Lung Macrophages
from Mice Injected with Corynebacteriumn parvum.
Int. J. Cancer, 13, 478.
SHAKIB, F., STANWORTH, D. R., DREW, R. & CATTY,
D. (1975) A Quantitative Study of the Distri-
bution of IgG sub-classes in a Group of Normal
Sera. J. Imnun. Methods. In the press.
SPIEGELBERG, H. L. (1974) Biological Activities of
Immunoglobulins of Different Classes and Sub-
classes. Adv. Immunol., 19, 259.
STIMSON, W. H. & SINCLAIR, M. (1974) An Immuno-
assay for a Pregnancy Associated a-macroglobulin
using Antibody-Enzyme Conjugates. FEBS
Letter8, 47, 190.
TUNSTALL, A. M., MERRIMAN, J. M. L., MILNE, I. &
JAMES, K. (1975) Normal and Pathological
Serum Levels of cx2-macroglobulins in Humans
and Mice. Br. J. Path., 28, 133.
WARR, G. W. & JAMES, K. (1975) Effect of Coryne-
bacterium parvum on the Class and Sub-class of
Antibody Produced in the Response of Different
Strains of Mice to Sheep Erythrocytes. Immun-
ology, 28, 431.
WOODRUFF, M. F. A. & BOAK, J. L. (1966) Inhibitory
Effect of Injection of Corynebacterium parvum on
the Growth of Tumour Transplants in Syngeneic
Hosts. Br. J. Cancer, 20, 345.
WOODRUFF, M. F. A. & DUNBAR, N. (1973) The
Effect of Corynebacterium par-vum and Other
Reticuloendothelial Stimulants on Transplanted
Tumours in Mice. In CibaFoundationSympo8ium
on Immunopotentiation. p. 287.
WOODRUFF, M. F. A., CLUNIE, G. J. A., MCBRIDE,
W. H., MCCORMACK, R. J. M., WALBAUM, P. R.
& JAMES, K. (1974a) L'effect de l'injection
intraveineuse et intramusculaire de Coryne-
bacterium parvum chez l'homme. Allerg.
Immunol., 6, 201.
WOODRUFF, M. F. A., MCBRIDE, W. H. & DUNBAR,
N. (1974b) Tumour Growth, Phagocytic Activity
and Antibody Response in C. parvum Treated
Mice. Clin. & exp. Immunol., 17, 509.
YOUNT, W. J., DORNER, M. M., KUNKEL, H. G. &
KABAT, E. A. (1968) Studies on Human Anti-
bodies. VI. Selective Variations in Subgroup
Composition and Genetic Markers. J. exp. Med.,
127, 633.